Figure 2.

The PFS and OS rates of patients with non-small cell lung cancer with anaplastic lymphoma kinase fusion. Kaplan-Meier survival analyses of patients with high vs. low p-c-Kit levels in their tumor samples. (A) Patients with high levels of p-c-Kit had significantly poorer PFS time (log-rank test, P=0.005). (B) Patients with high levels of p-c-Kit had significantly poorer OS time (log-rank test, P=0.002). PFS, progression-free survival; OS, overall survival; p-c-Kit, phosphorylated mast/stem cell growth factor receptor Kit.